Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide Gallbladder Emptying Trial
NCT02717858Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2016
- Primary completion
- Feb 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing Liraglutide with Placebo (2 arms). Primary endpoint: Maximum Postprandial Gallbladder Ejection Fraction at 12 weeks. Started Mar 2016; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02717858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02717858.